Targeted Therapy for Advanced Basal Cell Carcinoma: Uses and Limits

Targeted medicines can offer another treatment option when basal cell carcinoma (BCC) is advanced, returns after treatment, or cannot be treated with surgery or radiation. They act on signals that cancer cells use to grow. That makes them different from chemotherapy, which can also affect healthy cells that divide quickly. These medicines are used in selected cases; most BCC is treated with surgery or a topical medicine, and advanced disease is uncommon.

For someone considering treatment, the key questions are whether the cancer is suitable for a medicine that blocks its growth pathway, what other options fit the situation, and what side effects may matter. The decision depends on the tumor’s extent, previous treatment and the person’s health and circumstances. A dermatologist or cancer specialist can explain how these factors apply to an individual case.

How the treatment works

Many BCCs involve abnormal activity in the hedgehog pathway, a cellular signaling system that helps regulate growth and development. The pathway is especially active during embryo development. In adults, it is usually much less active, though it has roles in processes such as tissue repair.

Changes in cancer cells can keep hedgehog signals switched on, encouraging cells to multiply and tumors to grow. Medicines called hedgehog pathway inhibitors block these signals. In that sense, they target a feature of the tumor rather than broadly attacking cells because they divide quickly.

Targeted therapy is sometimes described as precision or personalized medicine because treatment is chosen with the person’s cancer and circumstances in mind. The general aim is to interfere with a particular growth mechanism while limiting effects on healthy cells. That does not mean side effects are absent: these medicines can cause significant problems, and some require urgent attention.

How it compares with other systemic treatment

Systemic medicines work throughout the body. For advanced BCC, targeted therapy and immunotherapy are among the systemic options used early in treatment. Chemotherapy is used less often, though it may be considered in some cases, including when other treatments haven’t worked.

The treatments act in different ways. Chemotherapy damages rapidly dividing cells, including some healthy cells in the skin, bone marrow and intestines. This broad effect can lead to problems such as hair loss, nausea and low blood counts. Hedgehog inhibitors instead block a molecular pathway that the tumor depends on for growth.

Immunotherapy works through the body’s defenses: it helps the immune system recognize and attack cancer cells. Unlike targeted therapy, it does not act by directly blocking the tumor’s hedgehog pathway. Which approach fits depends on the tumor, a person’s health and the goals of treatment.

When a specialist may consider it

Targeted therapy is generally reserved for particular situations. These can include cancer that has spread beyond its original site, cancer that has returned after surgery or radiation, or disease that cannot be treated with those methods. It may also be considered when removing a tumor would be difficult or could have substantial effects on function or appearance.

For example, a large tumor affecting the nose, eyelid or ear may require extensive surgery and reconstruction. In some cases, specialists have studied using a hedgehog inhibitor before surgery to shrink a tumor and potentially make the operation less complicated. This is called neoadjuvant treatment. The source describes this use as not approved, and says its suitability depends on the individual case and available evidence. A team of specialists can assess whether it is a reasonable option.

Two medicines used for advanced BCC

Two hedgehog pathway inhibitors are approved for advanced BCC: vismodegib (Erivedge) and sonidegib (Odomzo). Their uses overlap, but they are not described as interchangeable for every situation.

Vismodegib was approved in 2012. It is used for BCC that has spread to other parts of the body, for locally advanced disease that returns after surgery, or when surgery or radiation cannot be used. It is taken by mouth as a capsule once daily. Common side effects include muscle spasms, digestive problems, hair loss, tiredness and joint pain. Serious skin reactions and muscle problems can also occur and may need immediate care.

Sonidegib was approved in 2015 for locally advanced BCC that has returned after surgery or radiation, or cannot be treated with either. It is taken by mouth once daily on an empty stomach. Reported common side effects include muscle spasms, digestive problems, hair loss, itching, tiredness and joint pain. Serious muscle problems are also possible.

Both medicines can cause severe harm to a developing fetus. The source advises that women use birth control and men use condoms while taking either medicine. Anyone who could become pregnant, or whose partner could become pregnant, should discuss these risks and prevention with the prescribing clinician or pharmacist before treatment and during care.

What to discuss with the care team

These medicines can be useful when standard local treatments aren’t suitable, but their possible benefits and harms need to be weighed for each person. A discussion with a dermatologist or cancer specialist can cover the cancer’s location and extent, prior treatment, other health conditions, expected side effects and whether another approach may fit better. A pharmacist can help clarify medication precautions and potential interactions.

The practical takeaway is that targeted therapy is a specialized option for selected advanced or difficult-to-treat BCC. Understanding why it is being considered—and what symptoms or risks to raise with the care team—can help patients take part in decisions as treatment plans evolve.